Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity

Future Medicinal Chemistry

Volumn 1, Issue 5, 2009, Pages 947-967

  Seo, Hee Jeong ^a   Kim, Min Ju ^a   Song, Kwang Seop ^a   Lee, Sung Han ^a   Jung, Myung Eun ^a   Kim, Mi Soon ^a   Park, Hyun Ju ^b   Yoo, Jakyung ^b   Chang, Chong Hwan ^a   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; 1,3,4 THIADIAZOLE DERIVATIVE; 2 [1 (2 CHLOROPHENYL) 5 (4 CHLOROPHENYL) 4 (METHYLSULFONYL) 1H PYRAZOL 3 YL] 5 [1 (TRIFLUOROMETHYL)CYCLOBUTYL] 1,3,4 THIADIAZOLE; 2 [5 (4 BROMOPHENYL) 1 (2 CHLOROPHENYL) 4 (METHYLSULFONYL) 1H PYRAZOL 3 YL] 5 [1 (TRIFLUOROMETHYL)CYCLOBUTYL]1,3,4 THIADIAZOLE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; MALE; NONHUMAN; OBESITY; OXIDATION; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; BINDING SITES; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; HUMANS; MICE; OBESITY; OXADIAZOLES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 71749115522     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.64     Document Type: Article

References (37)

1. Bray GA. Obesity: the disease. J. Med. Chem. 49, 4001-4007 (2006).
2. WHO. Report of a WHO consultation on obesity. Obesity-preventing and managing a global epidemic. Geneva, Switzerland (2000).
3. Antel J, Gregory PC, Nordheim, U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J. Med. Chem. 49, 4008-4016 (2006).
4. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States. J. Am. Med. Assoc. 291, 1238-1245 (2004).
5. Hepworth D, Carpino PA, Black SC. Centrally acting anti-obesity agents. Annu. Rep. Med. Chem. 41, 77-97 (2006).
6. Pagotto U, Vicennati V, Pasquali, R. The endocannabinoid system and the treatment of obesity. Ann. Med. 37, 270 (2005).
7. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
8. Muineddu G, Ruiu S, Mussinu JM et al. Tricyclic pyrazoles part 2: synthesis and biological evaluation of novel 4,5-dihydro- 1H-benzo[g]indazole- based ligands for cannabinoid receptors. Bioorg. Med. Chem. 13, 3309-3320 (2005).
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
11. Lange JHM, Kruse CG. Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Discov. Dev. 7, 498-506 (2004).
12. Lange JHM, Kruse CG. Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today 10, 693-702 (2005).
13. Barth F. CB1 cannabinoid receptor antagonists. Annu. Rep. Med. Chem. 40, 103-118 (2005).
14. Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol. 6, 586-591 (2006).
15. Boström J, Berggren K, Greasley P, Wilstermann M. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. Bioorg. Med. Chem. 15, 4077-4084 (2007).
16. Lee SH, Seo HJ, Lee, SH et al. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 51(22), 7216-7233 (2008).
17. Lin LS, Lanza TJ, Jewell JP et al. Discovery of N-[(1S,2S)-3-(4- chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl) pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med. Chem. 49, 7584-7587 (2006).
18. Chen Cy, Frey LF, Shultz S et al. Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Org. Process Res. Dev. 11, 616-623 (2007).
19. Lin LS, Ha S, Ball RG et al. Conformational analysis and receptor docking of N-[(1S,2S)- 3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl- 2-{[5- (trifluoromethyl)pyridin-2-yl]oxy} propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J. Med. Chem. 51, 2108-2114 (2008).
20. Fong TM, Guan XM, Marsh DJ et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4- chlorophenyl)-2-(3- cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5- (trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 321, 1013-1022 (2007).
21. Lange JH, Coolen HK, van Stuivenberg HH et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. 47, 627 (2004).
22. Griffith DA, Hadcock JR, Balck SC et al. Discovery of 1-[9-(4-chlorophenyl)-8-(2- chlorophenyl)-9H-purin-6-yl]-4- ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J. Med. Chem. 52(2), 234-237 (2009).
23. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nature Rev. Drug Discov. 7, 961-962 (2008).
24. Lange JHM, Kruse CG. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chem. Rec. 8, 156-168 (2008).
25. Shim JY, Welsh WJ, Cartier E, Edwards JL, Howlett AC. molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4- dichlorophenyl)-4- methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J. Med. Chem. 45, 1447-1459 (2002).
26. Kang SY, Lee SH, Seo HJ et al. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Bioorg. Med. Chem. Lett. 18, 2384-2388 (2008).
27. Kim JY, Seo HJ, Lee SH et al. Diarylpyrazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists. Bioorg. Med. Chem. Lett. 19, 142-145 (2009).
28. Lee SH, Seo HJ, Kim MJ et al. Oxadiazolediarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands. Bioorg. Med. Chem. Lett. 19, 1899-1902 (2009).
29. Lan R, Liu Q, Fan P et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42, 769-776 (1999).
30. Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. J. Med. Chem. 46, 642-645 (2003).
31. Nimitz JS, Mosher HS. A new synthesis of a-keto esters and acids. J. Org. Chem. 46, 211-213 (1981).
32. Brain CT, Paul JM, Loong Y et al. Novel procedure for the synthesis of 1,3,4-oxadiazoles from 1,2-diacylhydrazines using polymer-supported Burgess reagent under microwave conditions. Tetrahedron Lett. 40, 3275-3278 (1999).
33. Brain CT, Brunton SA. Synthesis of 1,3,4-oxadiazoles using polymer-supported reagents. Synlett 40(16), 382 (2001).
34. Kiryanov AA, Sampson P, Seed AJ. Synthesis of 2-alkoxy-substituted thiophenes, 1,3-thiazoles, and related S-heterocycles via Lawesson's reagent-mediated cyclization under microwave irradiation: applications for liquid crystal synthesis, J. Org. Chem. 66, 7925-7929 (2001).
35. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264, 1352-1363 (1993).
36. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 462(1-3), 125-132 (2003).
37. Murphy JW, Kendall DA. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP55,940 but not SR141716A. Biochem. Pharmacol. 65, 1623-1631 (2003).